Book contents
- Seminars in the Psychotherapies
- College Seminars Series
- Seminars in the Psychotherapies
- Copyright page
- Reviews
- Contents
- Contributors
- Foreword
- Preface
- Part I Therapy Theory and Practice
- Part II Applied Psychotherapeutic Thinking
- Section 1 Psychological and Psychodynamic Approaches to Psychiatry
- Section 2 Work in Practice
- Section 3 Contemporary Developments
- Chapter 26 The Open Dialogue Approach
- Chapter 27 Neuropsychoanalysis and Relational Neuroscience
- Chapter 28 Psychedelic-Assisted Psychotherapy
- Chapter 29 Psychotherapeutic Development through the Life of the Psychiatrist
- Index
- References
Chapter 28 - Psychedelic-Assisted Psychotherapy
from Section 3 - Contemporary Developments
Published online by Cambridge University Press: 27 May 2021
By
Book contents
- Seminars in the Psychotherapies
- College Seminars Series
- Seminars in the Psychotherapies
- Copyright page
- Reviews
- Contents
- Contributors
- Foreword
- Preface
- Part I Therapy Theory and Practice
- Part II Applied Psychotherapeutic Thinking
- Section 1 Psychological and Psychodynamic Approaches to Psychiatry
- Section 2 Work in Practice
- Section 3 Contemporary Developments
- Chapter 26 The Open Dialogue Approach
- Chapter 27 Neuropsychoanalysis and Relational Neuroscience
- Chapter 28 Psychedelic-Assisted Psychotherapy
- Chapter 29 Psychotherapeutic Development through the Life of the Psychiatrist
- Index
- References
Summary
In recent years there has been a resumption of research into the potential therapeutic benefits of psychedelic1 drugs such as MDMA2, psilocybin and LSD3. Clinical research suggests significant efficacy for psychiatric disorders that have traditionally been hard to treat. The evidence base has accumulated to the point that psychedelic-assisted psychotherapy appears to be moving from a fringe subject to a significant new treatment method that all psychotherapists should at least be aware of and that some may develop into a special interest.
- Type
- Chapter
- Information
- Seminars in the Psychotherapies , pp. 363 - 372Publisher: Cambridge University PressPrint publication year: 2021
References
Freud, S. An outline of psycho-analysis. In Strachey, J, ed., The Standard Edition of the Complete Psychological Works of Sigmund Freud, Volume XXIII (1937–1939). Moses and Monotheism, An Outline of Psycho-Analysis and Other Works. London: Hogarth Press. 1964; pp. 139–208. (Original work published 1938)Google Scholar
Mithoefer, MC, Mithoefer, AT, Feduccia, AA et al. 3,4-methylenedioxymethamphetamine (MDMA) psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 2018; 5(6): 486–97.CrossRefGoogle ScholarPubMed
Mithoefer, M, Mithoefer, A, Jerome, L et al. A manual for MDMA-assisted psychotherapy in the treatment of PTSD (version 8). http://www.maps.org/research/mdma/mdma-research-timeline/4887-a-manual-for-mdma-assisted-psychotherapy-in-the-treatment-of-ptsd [Accessed 23/11/2020]Google Scholar
Sessa, B. The Psychedelic Renaissance, 2nd ed. London: Muswell Hill Press. 2017; p. 41.Google ScholarPubMed
Carhart-Harris, RL, Murphy, K, Leech, R et al. The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. Biol Psychiatry 2015; 78(8): 554–62.Google Scholar
Mithoefer, M. MDMA-assisted psychotherapy: how different is it from other psychotherapy? MAPS Bulletin Special Edition, Spring 2013. www.maps.org/news-letters/v23n1/v23n1_p10-14.pdf> [Accessed 23/11/2020]+[Accessed+23/11/2020]>Google Scholar
Gasser, P, Holstein, D, Michel, Y et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 2014; 202(7): 513–20.Google Scholar
Roseman, L, Nutt, D, Carhart-Harris, RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 2018; 8: 974.Google Scholar
Carhart-Harris, RL, Bolstridge, M, Rucker, J et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016; 3(7): 619–27.Google Scholar
Kurland, A, Savage, C, Pahnke, WN, Grof, S, Olsson, JE. LSD in the treatment of alcoholics. Pharmacopsychiatry 1971; 4(2): 83–94.Google Scholar
Pahnke, WN, Kurland, AA, Goodman, LE, Richards, WA. LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther 1969; 9: 144–52.Google ScholarPubMed
Cohen, S. Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis 1960; 130: 30–40.Google Scholar
Griffiths, RR, Bigelow, GE, Henningfield, JE. Similarities and animal and human drug-taking behaviour. In Mello, NK, ed., Advances in Substance Abuse. Vol. 1. Greenwich: JAI Press. 1980; pp. 1–90.Google Scholar
Griffiths, RR, Richards, WA, McCann, U, Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006; 187: 268–83.Google Scholar
Grof, S. Realms of the Human Unconscious: Observations from LSD Research. New York: Viking, 1975.Google Scholar
Piontelli, A. From Fetus to Child: Observational and Psychoanalytical Study. Hove: Routledge, 1992.Google Scholar
- 1
- Cited by